Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tocilizumab-conjugated cisplatin nanoparticles
- Development stage
- Preclinical
- Lead developer
- Huazhong University of Science and Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Parenteral
01
Overview
**Tocilizumab-conjugated cisplatin nanoparticles** are an investigational lipid-polymer hybrid nanomedicine designated **LPC-TCZ**. The formulation encapsulates the platinum chemotherapeutic cisplatin and is surface-functionalized with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody. It was reported in preclinical non-small-cell lung cancer models to combine cisplatin-mediated DNA damage with IL-6 receptor blockade, thereby suppressing IL-6/STAT3-associated epithelial-mesenchymal transition, cancer stem-cell features, chemoresistance, tumor growth, and metastasis. ([mdpi.com](https://www.mdpi.com/1999-4923/17/7/945))
- Other names
- LPC-TCZ
02
Targets
DNAIL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on tocilizumab-conjugated cisplatin nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tocilizumab-conjugated cisplatin nanoparticles.